MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem cells. This is a big step forward in a key treatment for blood cancers.
A transplant of hematopoietic stem cells (cells that give origin to blood cells) is often used as part of treatments for blood cancers. However, it’s not always easy to find a fully compatible donor. Because of this, high-risk patients often have to undergo haploidentical transplants with a partial match (usually the stem cells of a sibling or a parent).
Partial match transplants carry the risk of graft versus host disease (GvHD), a life-threatening immune reaction caused by the genetic disparity between patient and donor.
MolMed’s Zalmoxis is tackling this issue by genetically engineering donor immune system T-cells to carry an inducible ‘suicide gene‘. This gene can be used as a switch to control GvHD (something also engineered for CAR-T),